Tolvaptan is a vasopressin V2-receptor antagonist that has shown promise in treating
Autosomal Dominant Polycystic Kidney Disease (ADPKD). Tolvaptan was, however …

Background Many strategies regarding timing of native nephrectomies exist for patients with
symptomatic polycystic kidney disease (PCKD). Methods This is a single-center …

Background: This study aimed to evaluate the hospitalization rates for subarachnoid
hemorrhage (SAH) among renal transplant patients with adult polycystic kidney disease …

Purpose Bilateral nephrectomy is performed at times with renal transplantation. Though
surgical indications and timing of these two procedures have been described, there are no …

Аннотация Цель. Оценка возможностей применения лапароскопической
трансабдоминальной нефрэктомии (ЛНЭ) для хирургического лечения и подготовки к …

Autosomal dominant polycystic kidney disease (ADPKD) is the first genetic cause of end-
stage renal disease (ESRD) and the number of these patients who are listed for or receive a …

These guidelines address the management of patients with autosomal dominant polycystic
kidney disease who are candidates for kidney and/or liver transplantation. They include …

В ходе исследования проведен анализ результатов лечения 32 пациентов с аутосомно-
доминантным поликистозом почек (АДПП). В период с 2014 по 2016 г. этим больным …

Autosomal dominant polycystic kidney disease is the third most common cause of renal
failure with no definitive treatment available that can directly target the development and …

Autosomal dominant polycystic kidney disease (ADPKD) affects approximately 1 in 1,000
people in the general population. The natural history of ADPKD includes the progression of …